Avila Therapeutics appoints first CEO
This article was originally published in Scrip
Avila Therapeutics (US), an emerging biopharmaceutical company developing covalent drugs, has appointed Katrine Bosley chief executive officer. She joins from Adnexus, where she served as vice-president of business development and later as vice-president of strategic operations.
You may also be interested in...
Products from Novartis, Celgene and Merck could get an EU approval recommendation at this week's CHMP meeting.
As its CEO Jerome Carle steps down following a 67% slump in sales to date this year, UAE-based Julphar is hopeful of putting manufacturing problems behind it under a new management team.